XML 61 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaboration Agreements (Ipsen Collaboration) (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Dec. 31, 2016
USD ($)
Nov. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Jun. 30, 2017
USD ($)
milestone
Dec. 31, 2016
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Current portion of deferred revenue $ 19,665,000 [1]     $ 31,255,000 $ 19,665,000 [1] $ 31,255,000  
Long-term portion of deferred revenue 237,094,000 [1]     253,663,000 237,094,000 [1] $ 253,663,000  
GlaxoSmithKline [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Percent of royalty on net sale           3.00%  
Collaborative Arrangement with Ipsen [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront and milestone payments     $ 200,000,000        
Research and development arrangement performed for others, reimbursement for costs incurred, percent           35.00%  
Reimbursements of certain clinical programs paid       2,100,000      
Current portion of deferred revenue       19,000,000   $ 19,000,000  
Long-term portion of deferred revenue       $ 219,700,000   $ 219,700,000  
Collaborative Arrangement with Ipsen [Member] | Reclassification Adjustment [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred revenue reclassified             $ 9,000,000
Collaborative Arrangement with Ipsen [Member] | Initial [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Percent of royalty on net sale           2.00%  
Royalty tier           $ 50,000,000  
Collaborative Arrangement with Ipsen [Member] | Second [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Percent of royalty on net sale           12.00%  
Royalty tier           $ 100,000,000  
Collaborative Arrangement with Ipsen [Member] | Initial and Second [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Royalty tier           $ 150,000,000  
Collaborative Arrangement with Ipsen [Member] | Initial and Second [Member] | Minimum [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Percent of royalty on net sale           22.00%  
Collaborative Arrangement with Ipsen [Member] | Initial and Second [Member] | Maximum [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Percent of royalty on net sale           26.00%  
Collaborative Arrangement with Ipsen, Consideration for Commercialization Rights [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue recognized, milestones $ 10,000,000            
Collaborative Arrangement with Ipsen, Approval of Cabozantinib by EC in Second-Line RCC [Member] | CABOMETYX [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue recognized, milestones   $ 60,000,000          
Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member] | CABOMETYX [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Number of milestones achieved | milestone       2      
Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member] | United Kingdom [Member] | CABOMETYX [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue recognized, milestones         $ 10,000,000    
Collaborative Arrangement with Ipsen, First Commercial Sales of Product [Member] | Germany [Member] | CABOMETYX [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue recognized, milestones       $ 10,000,000      
[1] The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.